19:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100 patients with hypertriglyceridemia and established cardiovascular disease (CVD). AKCEA-APOCIII-LRx is a ligand conjugated antisense version...
21:06 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

AKCEA-APO(a)-LRx: Ph IIb started

Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease. In January, Ionis and...
18:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea...
23:50 , Mar 27, 2017 |  BC Extra  |  Financial News

Ionis lipid spinout Akcea targets $100M IPO

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million, according to a regulatory filing. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN)...
19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

Ionis, Novartis deal

Ionis and its Akcea Therapeutics Inc. subsidiary granted Novartis exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are antisense therapies for cardiovascular disorders. Ionis and Akcea will receive an upfront...
23:51 , Jan 6, 2017 |  BC Extra  |  Company News

Ionis, Novartis forge cardiovascular deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and its Akcea Therapeutics subsidiary granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are antisense therapies for cardiovascular disorders. Ionis and Akcea...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Enhancing hepatocyte uptake of antisense oligonucleotides (ASOs) via conjugation to N-acetylgalactosamine (GalNAc) clusters targeting asialoglycopro

Drug delivery TECHNOLOGY: Other Conjugating ASOs to GalNAc clusters targeting ASGR1 could help improve hepatocyte uptake of antisense therapeutics. The GalNAc cluster consisted of a tris(hydroxymethyl)aminomethane scaffold containing a linker that could be conjugated to the 5'...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS-APO: Phase I/IIa data

A double-blind, placebo-controlled Phase I/IIa trial in 50 patients with elevated LPA levels showed that single subcutaneous doses of ISIS-APO(a)-LRx led to mean and maximum reductions in LPA levels at day 30 of 26.2% and...
02:49 , Nov 10, 2015 |  BC Extra  |  Clinical News

Isis climbs on LPA data

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) jumped $6.90 (12%) to $62.77 on Monday after reporting that its ISIS-APO(a)Rx and ISIS-APO(a)-LRx significantly reduced lipoprotein(a) (LPA) in clinical trials to treat patients with high LPA levels. ISIS-APO(a)Rx is an...